TL;DR
This paper presents a validated Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) method for assessing the dissolution of Levofloxacin 750 mg tablets. The developed method is shown to be precise, accurate, linear, and robust, ensuring reliable quality control for this important antibiotic.
What Problem Does This Paper Address?
Ensuring the quality and consistent performance of pharmaceutical products is paramount, especially for antibiotics like Levofloxacin, which are crucial for treating various bacterial infections. The dissolution test is a critical in vitro method used to predict how a drug will perform in the body (in vivo) by measuring how quickly the active ingredient is released from its dosage form. However, developing and validating a robust dissolution method, particularly for potent drugs like Levofloxacin, can be complex. This paper addresses the need for a reliable, validated RP-HPLC method to accurately assess the dissolution of Levofloxacin 750 mg tablets, enabling consistent lot-to-lot quality control and comparability between generic and brand-name products.
Methods
The core of this study involves the development and validation of a dissolution method for Levofloxacin 750 mg tablets using RP-HPLC. The method was validated according to International Council for Harmonisation (ICH) guidelines, focusing on key parameters:
- System Precision: Assessed by repeated injections of a standard solution to ensure the analytical system's stability and reproducibility.
- Method Precision: Evaluated by analyzing multiple samples of the same batch to confirm the method's consistency.
- Linearity: Determined by analyzing solutions at varying concentrations (60% to 140% of nominal concentration) to establish a direct proportional relationship between concentration and peak area.
- Range: Assessed by injecting samples at the lower (60%) and upper (140%) limits of the linearity study to confirm the method's suitability across this range.
- Dissolution Testing: The actual dissolution of Levofloxacin 750 mg tablets (both Trevox and Levox brands) was performed in 0.1N HCl for 30 and 45 minutes. The released drug was then quantified using the validated RP-HPLC method.
The instrumentation used included an Adept series CECIL HPLC system with a gradient pump, UV detector, and degasser, along with a manual injector and a dissolution tester.
Datasets
Not discussed in the paper. The study utilizes reference standards and commercially available Levofloxacin tablets (Trevox and Levox) as samples.
Key Insights and Ideas
- RP-HPLC as a Robust Tool: The study successfully demonstrates that RP-HPLC is a suitable and sensitive technique for quantifying Levofloxacin released during dissolution testing.
- Method Validation is Crucial: The comprehensive validation process, covering precision, linearity, and range, provides strong evidence for the method's reliability and suitability for routine quality control.
- Brand Comparability: The method's ability to accurately assess dissolution across different Levofloxacin tablet brands (Trevox and Levox) is a significant step towards ensuring bioequivalence and therapeutic equivalence.
- Meeting Stringent Criteria: The method consistently met predefined acceptance criteria for all validation parameters, highlighting its robustness.
Key Results
The validated RP-HPLC dissolution method for Levofloxacin 750 mg tablets demonstrated:
- System Precision: %RSD was 0.51%, well below the acceptance criterion of ≤ 2.0%.
- Method Precision: Relative Standard Deviation (%RSD) was 1.68%, also below the acceptance criterion of ≤ 2.0%.
- Linearity: An excellent correlation coefficient (r² = 0.9993) was achieved, indicating a strong linear relationship between concentration and peak area over the tested range (60%-140%).
- Range: The method proved suitable, with %RSD within limits for both 60% and 140% concentration levels.
- Dissolution Performance: All tested tablets (Trevox and Levox) met the specified dissolution criteria: ≥70% dissolved at 30 minutes and ≥75% dissolved at 45 minutes. The average dissolution for Trevox was 93.30% at 30 minutes and 98.40% at 45 minutes. For Levox, the average dissolution was 92.09% at 30 minutes and 99.05% at 45 minutes.
Limitations and Future Work
- Stability Testing: The authors acknowledge that stability testing could not be completed due to time constraints. This is a crucial next step to fully establish the method's long-term reliability.
- In Vivo Correlation: While the dissolution test is designed to reflect in vivo performance, direct correlation studies were not part of this paper.
- Future Work: The authors suggest that the current data supports the method's reliability for routine analyses and its potential inclusion in pharmaceutical monographs, pending further stability evaluation. The validated method is presented as a practical and transferable approach for quality assurance.
Summary updated